Introduction
Aberrant glycosylation is thought to be a characteristic feature of cancer cells, and in particular, altered sialylation is associated with malignant properties including invasiveness and metastasis (Hakomori, 1996; Kim and Varki, 1997; Dennis et al., 1999; Hakomori, 2002) . Despite numbers of reports describing an involvement of sialic acids in cancer, it is still uncertain what might be the causes of such aberrations and their consequences. To elucidate molecular mechanisms and the significance of aberrant sialylation, our studies have been focused on sialidases, which are responsible for the removal of sialic acids from glycoproteins and glycolipids. Mammalian sialidases have been classified into four types (designated as Neu1, Neu2, Neu3 and Neu4) differing in subcellular localization and enzymatic properties (Monti et al., 2002; . Although functional aspects of each individual sialidase are not fully understood, they are likely to be involved in modulation of cell physiology through desialylation of glycoconjugate molecules, depending on their particular subcellular location and substrate specificity, as well as in catabolism itself of the molecules. Expression of the sialidases consistently fluctuates with cell differentiation, cell growth and malignant transformation . Among the sialidases, Neu3 is a key enzyme for ganglioside degradation, and is unique in localizing mainly in plasma membrane and in hydrolyzing specifically gangliosides Wada et al., 1999; Monti et al., 2000) . Gangliosides have been shown to influence various biological processes at cell surfaces and in fact, our recent reports have presented evidence that Neu3 participates in neuronal differentiation (Hasegawa et al., 2000; Da Silva et al., 2005) , transmembrane signaling (Sasaki et al., 2003; Kato et al., 2005; Ueno et al., 2006) and carcinogenesis (Kakugawa et al., 2002; Ueno et al., 2006) through ganglioside modulation.
We previously cloned a human plasma membraneassociated sialidase, NEU3 , and demonstrated a marked increase of the gene expression in human cancers including colon (Kakugawa et al., 2002) and renal (Ueno et al., 2006) cancers as compared with adjacent non-tumor tissues. Upregulation of NEU3 caused suppression of cell differentiation and apoptosis and promotion of invasion and motility by augmenting the functions of molecules being activated in cancer cells (Kato et al., 2005) , indicating that the sialidase is indeed closely related to malignant phenotype. To determine functional roles and possible targets of NEU3 in cancer, its gene expression was modified by knockdown with a small interference RNA (siRNA) or by overexpression in human carcinoma cells. In this work, we found that the gene plays a crucial role in cancer cell survival via activation of Ras and the subsequent pathway.
Results
Apoptosis induction by siRNA-mediated silencing of the sialidase NEU3 The ability of the siRNA to specifically silence the human sialidase gene in HeLa cells was first evaluated. As a control for specificity, two non-targeting siRNAs (scrambled control and non-specific control) were employed. At 48 h after transfection with siRNA, NEU3 mRNA levels were estimated by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal control. As shown in Figure 1a , in comparison with two control siRNAs, the relative expression levels were 5.172.4, 18.2711.3 and 83.2715 .4%, for NEU3 targeting siRNAs , siRNA-3, -1 and -2, respectively. When sialidase activity was assayed with ganglioside GM3 as substrates, the cells transfected with the most effective siRNA (siRNA3) showed a great reduction in the activity, but those with controls were affected only to a minor extent as compared with untreated cells (Figure 1b) . The activity was mostly owing to endogenous NEU3, because the expression level for NEU4 also acting on gangliosides was less than a twentieth of that of NEU3 in the cells, when assessed by the RT-PCR. The siRNA effect was further confirmed by immunoblotting with anti-NEU3 monoclonal antibody. As shown in Figure 1c , either siRNA3 or siRNA1 reduced significantly the protein amount of endogenous NEU3. These siRNAs did not exert any influence on the expression of other human sialidases. We then measured cell viability and apoptosis in transfected HeLa cells using terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. A TUNEL assay performed at 72-96 h indicated that most of the cells were undergoing apoptosis with siRNA3 without any special stimuli, but no influence was noted with the scrambled control ( Figure 1d) . MTT assays at 24-72 h after transfection showed inhibition of cell proliferation with NEU3 targeting siRNAs and the extent seemed to be dependent on the mRNA reduction rate under conditions whereby controls had no effect on cell viability or growth (Figure 1e ). We next examined the effect of NEU3 silencing on a wider variety of cells by MTT assay (Figure 2 ). Similar to the case of HeLa cells, transfection of siRNA3 into colon HT-29 and breast MCF-7 carcinoma cells showed a marked decrease in cell growth, as compared with scrambled control. However, interestingly, the same treatment did not affect growth of non-cancerous human fibroblast WI-38 and NHDF cells and keratinocyte NHEK cells, despite significant reduction (66, 92 and 64%, respectively) in NEU3 mRNA. This ineffectiveness on cell viability does not seem to be due to the difference in the turn-over of endogenous NEU3 protein, because the treatment of NHEK cells with siRNA3 resulted in decrease in the protein level to such an extent that HeLa cells were affected (Figure 1c) , as assessed by immunoblotting (data not shown).
Regulation of apoptosis and Ras signaling by NEU3
To explore the possible target(s) of NEU3, we compared functional differences in molecules regulating apoptosis Sialidase as a key regulator of cell survival T Wada et al signaling between NEU3 silencing and overexpressing HeLa cells. NEU3 transfection resulted in over 20-fold increase in sialidase activity towards gangliosides (3775 as compared with 1.570.4 U/mg protein for the vectortransfectants). First, we evaluated gene expression of apoptosis-related molecules, Bax, Bcl-xL and melanoma differentiation associated gene-7 (mda 7, differentiation and apoptosis-inducing protein) (Dent et al., 2005) and CMP sialic acid: lactosylceramide a2-3sialyltransferase (GM3 synthase) by real-time RT-PCR ( Figure 3a ). NEU3 silencing caused significant elevation of mda 7 mRNA accompanied by decrease in the Bcl-xL level, whereas NEU3 overexpression showed the opposite tendency. Interestingly, GM3 synthase level, which has been described to be increased during cell apoptosis (Sohn et al., 2006; Valaperta et al., 2006) , was also elevated markedly in siRNA3-treated cells, and only to a small extent in NEU3-transfected cells. Normal NHDF and NHEK cells did not show any significant change in these mRNA levels even after the siRNA treatment or NEU3 overexpression (data not shown). HeLa cells were then treated with anti-Fas plus cycloheximide (Holmstrom et al., 1999) to induce apoptosis in NEU3 silencing or overexpressing cells, and caspase-3 activity was measured by immunoblotting the active fragments ( Figure 3b ). In consistent with the data above on mRNA levels, introduction of siRNA3 caused higher caspase-3 activation in contrast to the decreased activity by NEU3 overexpression, as compared with respective controls. Next, we studied on mitogen-activated protein (MAP) kinase and phosphoinositide-3 (PI3)-kinase cascades, as determined by immunoblotting, as they have been shown to be essential for regulation of cell apoptosis through Ras activation (Adjei, 2001; Cox and Der, 2003) . NEU3 silencing reduced phosphorylation of extracellular signal-regulated kinases (ERK) especially obviously with a growth factor such as EGF (Figure 4a ), whereas NEU3 overexpression enhanced phosphorylation of ERK and the activation was more evident when treated with EGF to make the changes clearer ( Figure 4b , left panel). The overexpression also brought about increased phosphorylation of Akt at threonine-308, but not significantly at serine-473 ( Figure 4b , right panel), suggesting that Akt might be activated but not to the full extent in this cell system, as reported that the former is essential for Akt activation under the regulation of PI3-kinase and the latter is required for maximal activity (Testa and Bellacosa, 2001 ). The results were consistent with those obtained in the experiments using MAP kinase kinase 1 inhibitor, PD98059 and PI3 kinase inhibitor, wortmannin. When apoptosis was induced in HeLa cells by treatment with anti-Fas antibody plus cycloheximide, NEU3-induced suppression of apoptosis was almost cancelled in the presence of PD98059, but weak effects of wortmannin (data not shown). In contrast to ERK and Akt, there was no change in JNK and p38 by NEU3 overexpression (data not shown). We then found that the silencing diminished ( Figure 4c Sialidase as a key regulator of cell survival T Wada et al clearly with EGF, and promotion of Ras activation by NEU3 occurred without any growth stimuli, even under serum-depleted conditions (Figure 4d , left panel), although NEU3 transfection exerted no significant effects on cell growth (data not shown). To cast light on possible steps leading to Ras activation, inhibitors of protein kinases upstream Ras were added to the culture. Either a Src kinase inhibitor, PP2 or an EGFR inhibitor, AG1478 reduced the NEU3-induced Ras activation to the nearly same level as the vector control (Figure 4d, right panel) . These data indicate that stimulation of Ras activity by NEU3 may be coupled to tyrosine kinases including Src and EGFR kinases. For clarification, we tested whether NEU3 stimulates EGFR phosphorylation. As expected from the previous reports (Bremer et al., 1986; Wang et al., 2003) describing inhibition of EGFR tyrosine phosphorylation by GM3, siRNA3 introduction reduced phosphorylation of EGFR (Figure 5a , left panel) and in contrast, the overexpression promoted phosphorylation (Figure 5a , right panel) and the receptor dimerization ( Figure 5b ) in response to EGF. It is interesting to note that using anti-phospho-EGF receptor antibodies to specific tyrosine residues, the level of EGFR phosphorylation at tyrosine (Tyr)-845 was the most highest among those at Tyr-992, 1045, 1068, 1148 and 1173 in NEU3 transfected HeLa cells (data not shown), raising the possibility that NEU3 may largely stimulate EGFR phosphorylation that Src kinase is involved in (Biscardi et al., 1999) . Opposite to the case of NEU3 transfection, the levels at Tyr-845 were markedly decreased by NEU3 silencing. Furthermore, NEU3 co-immunoprecipitated with the EGF receptor, and EGF stimulation yielded a higher amount of immunoprecipitable NEU3 (Figure 5c ), although NEU3 was not co-precipitated with activated Ras protein under the same condition. 
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These results indicate that NEU3 suppresses apoptosis of cancer cells by promoting EGF receptor phosphorylation probably through its association with EGFR and consequently activation of Ras cascades, especially via Ras/ERK pathway.
Ganglioside alterations induced by NEU3 silencing or overexpression Gangliosides extracted from NEU3 silencing or overexpressing HeLa cells were fractionated by thin layer chromatography (TLC) (Figure 6a ). In comparison with the respective control cells, two separate transfectants (NEU3-1 and NEU3-2 cells) showed increase in the glycolipid with similar TLC mobility to lactosylceramide (LacCer) and undetectable change in the component having similar mobility to GM3, as shown in Figure 6a , right panel. These data do not seem to be contradictory to each other, because the GM3 synthase level was slightly increased in NEU3-transfected cells, as shown in Figure 3a , probably leading to compensation for GM3 reduced by NEU3. Although these glycolipids were hardly altered by treatment with siRNA3, the glycolipid corresponding to globotriaosylceramide (Gb3) was increased in the cells but no increase in ceramide (Figure 6a, left panel) . Quantitative analysis of the intensity of these glycolipid bands revealed that the to the culture, the HeLa cells were cultured for 24 h followed by 16 h serumstarvation, and treated with or without EGF for 15 min. EGFR phosphorylation was then measured. These experiments were repeated two times and they showed similar results.
changes were statistically significant (by Student's t-test): the ratio of increase in the glycolipid corresponding to LacCer by NEU3 overexpression was 2.470.79-fold (n ¼ 6, P ¼ 0.002), and that for Gb3 by NEU3 silencing was 2.170.15-fold (n ¼ 3, P ¼ 0.04). Consistent with the Gb3 increase, Gb3 synthase (a1-4 galactosyltransferase) mRNA level was elevated in siRNA3-treated cells (Figure 6b ). The relative levels were 0.8470.14 and 1.367023 (n ¼ 4, P ¼ 0.04, by Student's t-test) for control and siRNA3-treated cells, respectively, indicating that an activation of globoside biosynthesis occurred as a consequence of NEU3 silencing. It should be noted here that normal NHEK cells treated with siRNA3 showed a slight increase in Gb3 together with GM3 but no change in LacCer (data not shown). We then determined by MTT assay, whether increase in these glycolipids could affect cell viability in siRNA3-treated and control cells (Figure 6c ). LacCer rescued cell survival induced by siRNA3 to some extent without a significant influence in the control cells, but Gb3 showed a tendency to decrease cell growth in both the silencing and control cells. Thus, these glycolipids might be possible components involved in cell apoptosis of cancer cells. However, there is ambiguity in Gb3 effects, because the increase did not induce apoptosis in NHEK cells as described earlier, although it is distinct from the case of cancer cells in GM3 increase level. To verify further LacCer effects, the cells were treated with the glycolipids. As shown in Figure 6d , significant promotion of EGFR phosphorylation was observed by the treatment in response to EGF in HeLa cells, although increasing the concentration tends to decrease the effects, indicating accumulation of the glycolipids as the results of the sialidase reaction may lead to the apoptosis suppression subsequent to the activation of EGF signaling.
Discussion
We here demonstrated for the first time that siRNAmediated reduction in sialidase NEU3 induces apoptosis in human cancer cells, but not normal cells, consistent with our previous finding of apoptosis suppression with increased expression of NEU3 in colon and renal cancers. The siRNA introduction also increased gene expression of molecules related to apoptosis and reduced malignancy, including mda7 and GM3 synthase. The observations with NEU3 overexpressing cells revealed that NEU3 indeed activated Ras which was decreased with siRNA, suggesting a role in blocking apoptosis. As NEU3-induced Ras activation was abrogated by the inhibitors for EGFR and Src kinase, the upstream target for NEU3 would be these tyrosine kinases. In fact, NEU3 greatly promoted EGFR phosphorylation in response to EGF, possibly by association with the receptor and by modulation of gangliosides including LacCer. Maintaining Ras activity at a certain level by endogenous NEU3 appears to be essential for cancer cell survival. Although NEU3 showed a remarkable stimulation of Ras activation with EGF ( Figure 4 ), Ras activation occurred without any specific stimuli, even under serum-starved conditions. Therefore, Ras protein itself may be a crucial target of NEU3 for regulation of apoptosis, through activation of downstream molecules like ERK and Akt (Adjei, 2001; Cox and Der, 2003) . In particular, ERK pathway would be essential for apoptosis regulation by NEU3, consistent with the previous reports that ERK overrides apoptosis signaling from the Fas receptor (Holmstrom et al., 1999; Tran et al., 2001) and that phosphorylation of caspase-9 by ERK promotes cell survival (Allan et al., 2003) .
Although it is still unclear how NEU3 regulates Ras and the downstream targets such as ERK and Akt, ganglioside modulation as a consequence of catalytic reaction could be a major factor for the activation leading to suppression of apoptosis. Analysis of glycolipids from HeLa cells by TLC showed significant increase in LacCer by NEU3 and in Gb3 by siRNA3 transfection. The former change was consistent with those observed previously in colon cancer, possibly owing to enhanced hydrolysis of GM3, and the latter change might be at least caused by activation of Gb3 synthase, as shown in Figure 6b . Interestingly, Gb3 has been characterized as the CD77 differentiation antigen inducing apoptosis (Mangeney et al., 1991) . In addition to the glycolipid products, NEU3 might exert an influence on the signaling by interacting with some related molecules including EGFR, as shown in Figure 5c . It is feasible because we found previously that NEU3 actually interacts with caveolin-1 (Wang et al., 2002) or Grb-2 (Sasaki et al., 2003) .
The reason that NEU3 silencing did not affect apoptosis of normal cells is probably correlated with expression levels of NEU3 and GM3 synthase. The latter enzyme was unexpectedly increased to a great extent in siRNA3-treated HeLa cells but only slightly (1.1371.26-fold) in NHEK cells. When endogenous mRNA levels of NEU3 and GM3 synthase were compared, normal NHEK and NHDF cells possessed lower NEU3 levels (40-60% of that of HeLa cells) and in contrast, much higher levels in GM3 synthase (200-350% of that of HeLa cells). Although we do not know at present the mechanism of the GM3 synthase activation by NEU3 silencing that seems contradictory from a physiological point of view, GM3 synthase activation would be necessary for apoptosis induction. In this context, our results are consistent with those by other investigators that GM3 synthase is upregulated during cell apoptosis (Sohn et al., 2006; Valaperta et al., 2006) and downregulated in malignant transformation (Watanabe et al., 2002; Miura et al., 2004) . GM3 synthase activation in our experiments, however, occurred in cancer cell death, and in neuronal cell death in the report of Sohn et al. (2006) . As neuronal cells express relatively high NEU3 level , it would be interesting to know, whether NEU3 reduction is observed during apoptosis. In the report by Valaperta et al. (2006) introduction of mouse Neu3 gene into human fibroblasts caused apoptosis by increasing ceramide and GM3 synthase level, but no change in Gb3 synthase. Our results hardly showed significant increase of GM3 synthase level in normal NHEK cells by NEU3 overexpression (data not shown), but NEU3 silencing of HeLa cells induced Gb3 as well as GM3 synthase activation without ceramide increase, suggesting that this difference may be at least partly dependent on cell types. However, present results reveal that NEU3 and GM3 synthase would behave in opposite way in apoptosis of cancer cells. We can conclude here that siRNA-mediated silencing of the NEU3 gene induces apoptosis of cancer cells through reduction of Ras activation, and therefore that NEU3 is a key regulator for cancer cell survival, indicating the sialidase to be a good potential target for antineoplastic therapy.
Materials and methods

Cells and DNA transfection
Human carcinoma cells (HeLa , MCF-7 and HT-29) and noncancerous cells (WI-38, NHDF and NHEK) were cultured and transiently transfected as described in the Supplementary section.
Synthesis of siRNA and transfection siRNAs targeting NEU3 were siRNA1 (GTATACCTACTA CATCCCT), siRNA 2 (GTGAAGGCTTTCAGAGACT) and siRNA 3 (AAGGGAGTGTGGTAAGTTT). Scrambled siRNA, Sc (GCGATTAATGTAGGTTCGA) and nonspecific control were used as non-targeting siRNAs. Transfection was performed as described in the Supplementary section.
Quantitative analysis of transcripts by real-time PCR
Quantitative analysis of the transcripts for NEU3 and other apoptosis-related molecules was performed by real-time PCR using a LightCycler rapid thermal cycler system (Roche, Basel, Switzerland) as described previously . The primers' information was included as Supplementary materials.
Sialidase assays
Sialidase activity was assayed with GM3 substrate and Triton X-100 as described in the Supplementary section. The sialic acid released was determined by fluorometric HPLC with malononitrile (Li, 1992) .
Immunoblotting and Ras-activation assays
The cell lysates or immunoprecipitates were analysed by immunoblotting with the respective antibodies. Ras activity was measured using Raf-1 RBD-agarose. The detailed information was shown in the Supplementary section.
Measurement of cell viability and apoptosis
Cell growth and viability were determined using MTT assays and apoptosis was assayed with a TUNEL assay kit (Roche) as described in the Supplementary section.
Abbreviations
Gb3, globotriaosylceramide; LacCer, lactosylceramide; mda 7, melanoma differentiation associated gene-7.
